Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of Fludara plus alemtuzumab vs Fludara alone in second-line B-cell chronic lymphocytic leukemia
2004-000149-39Phase 3Completed
- Sponsor
- Sanofi
- Start
- Feb 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) comparing Fludara plus Campath with Fludara alone (2 arms). Primary endpoints: Efficacy comparison of fludarabine plus alemtuzumab vs fludarabine alone and Safety and tolerability of fludarabine plus alemtuzumab vs fludarabine alone. Started Feb 2007; status: completed.
02
Drugs
alemtuzumabfludarabine
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2004-000149-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000149-39.